Stamford, CT -- (SBWIRE) -- 01/23/2014 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: IsoRay, Inc. (NYSEMKT:ISR), Timmins Gold Corp (NYSEMKT:TGD), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Delcath Systems, Inc. (NASDAQ:DCTH)
IsoRay, Inc. (NYSEMKT:ISR) opened the session at $0.95, trading in a range of $0.76 - $0.97. The stock showed a negative performance of -14.44% in the last trading session from its previous close of $ 0.935 and closed at $0.800. The stock traded on a volume of 2.53 million shares and the average volume of the stock remained 1.41 million shares. IsoRay, Inc. (IsoRay) develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association for treatment for all solid tumor applications using Cesium-131.
Has ISR Found The Bottom and Ready To Move Up? Find Out Here
Timmins Gold Corp (NYSEMKT:TGD) traded 1.98 million shares in the last business day while the average volume of the stock remained 351,585 shares. The stock showed a negative movement of -12.74% to end at $1.37. The 52 week range of the stock remained $0.97 - $3.04. Timmins Gold Corp. (Timmins) is a gold mining and exploration company. The Company is engaged in exploration, mine development and the mining and extraction of precious metals, primarily gold. Its primary asset and material mineral property is the San Francisco Gold Property located in Sonora, Mexico, which includes the Company’s only operating mine (the Mine). Its projects include El Capomo Property, Timm Property, El Picacho Property, Patricia and Norma Property, San Onesimo, Zindy and San Fernando Properties.
Has TGD Found The Bottom And Ready To Gain Momentum? Find Out Here
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) reported 6.04 million shares were exchanged during the last trade, while the average volume is about 4.87 million shares. The stock dropped -9.74% and finished the day at $1.39. The beta of the stock is recorded at 2.64. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Why Should Investors Buy IMUC After the Recent Fall? Just Go Here and Find Out
Delcath Systems, Inc. (NASDAQ:DCTH) shares dropped -7.41 percent from its previous close of $0.378 to close at $0.350. Traded with volume of 6.21 million shares in the prior session and the average volume of the stock remained 5.76 million shares. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system.
Will DCTH Get Buyers Even After The Recent Rally? Find Out Here
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)